Table 3. Bivariate analysis of effectiveness evaluated by viral suppression according to follow-up time and patients’ characteristics. Belo Horizonte, State of Minas Gerais, 2015. (n = 440).
| Variable | 6 months | 12 months | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| OR | 95%CI | p | OR | 95%CI | p | |
| Sociodemographic | ||||||
|
| ||||||
| Sex (male) | 0.62 | 0.34–1.12 | 0.115 | 0.61 | 0.30–1.18 | 0.159 |
| Age (> 36 years) | 0.83 | 0.51–1.37 | 0.474 | 1.33 | 0.75–2.36 | 0.333 |
| Level of education (up to complete primary) | 0.78 | 0.48–1.27 | 0.314 | 0.97 | 0.56–1.67 | 0.900 |
| Race/Skin color (brown) | 0.62 | 0.38–1.02 | 0.060 | 1.10 | 0.60–2.00 | 0.763 |
| Marital status (single, divorced, widowed) | 1.03 | 0.62–1.71 | 0.912 | 1.26 | 0.69–2.31 | 0.451 |
| Employment (no) | 1.23 | 0.72–2.08 | 0.445 | 1.46 | 0.81–2.64 | 0.203 |
| Children (yes) | 0.88 | 0.53–1.47 | 0.626 | 0.71 | 0.40–1.27 | 0.245 |
|
| ||||||
| Clinical | ||||||
|
| ||||||
| HIV Risk/Exposure (MSM versus heterosexuals, IDU, others) | 1.00 | 0.58–1.72 | 0.992 | 1.59 | 0.80–3.16 | 0.183 |
| Viral load before ART (> 100,000 copies/ml) | 0.35 | 0.19–0.65 | 0.001 | 0.54 | 0.32–0.94 | 0.030 |
| AIDSa (yes) | 0.27 | 0.16–0.46 | 0.000 | 0.57 | 0.32–1.01 | 0.053 |
| Hepatitis B or C (yes) | 0.50 | 0.14–1.81 | 0.289 | - | - | 0.999 |
| Mental disorder (yes) | 0.63 | 0.37–1.10 | 0.101 | 0.61 | 0.33–1.12 | 0.108 |
| Hospitalization in previous year (yes) | 0.45 | 0.27–0.75 | 0.002 | 0.87 | 0.49–1.53 | 0.625 |
| Hospitalization during follow-up (yes) | 0.72 | 0.40–1.27 | 0.255 | 1.01 | 0.49–2.07 | 0.981 |
|
| ||||||
| ART-related | ||||||
|
| ||||||
| Initial treatment (hospital level) | 0.40 | 0.24–0.66 | 0.000 | 0.91 | 0.50–1.64 | 0.749 |
| Initial year of treatment (2015) | 1.73 | 1.05–2.85 | 0.030 | 1.00 | 0.57–1.77 | 0.999 |
| Initial ART regimen (PI versus NNRTI) | 0.70 | 0.29–1.69 | 0.431 | 0.68 | 0.26–1.77 | 0.431 |
| Initial ART regimen (MTR) | 0.57 | 0.34–0.97 | 0.036 | 0.97 | 0.55–1.74 | 0.929 |
| Time between diagnosis and ART (> 2 months) | 1.70 | 1.02–2.84 | 0.043 | 0.68 | 0.39–1.21 | 0.189 |
| Record of AR to ART (yes) | 0.88 | 0.53–1.43 | 0.597 | 0.99 | 0.56–1.74 | 0.963 |
| ARV switchb (yes) | 0.24 | 0.14–0.42 | 0.000 | 0.52 | 0.28–0.95 | 0.035 |
| Adherence to ART in 6 months (yes) | 2.28 | 1.25–4.14 | 0.007 | - | - | - |
| Adherence to ART in 12 months (yes) | - | - | - | 4.04 | 2.24–7.31 | 0.000 |
| Effectiveness at 6 months (yes) | - | - | - | 7.78 | 3.83–15.78 | 0.000 |
|
| ||||||
| Behavioral and lifestyle | ||||||
|
| ||||||
| Tobacco use in life (yes) | 0.72 | 0.41–1.28 | 0.265 | 0.60 | 0.31–1.16 | 0.127 |
| Alcohol use in life (yes) | 0.86 | 0.46–1.28 | 0.631 | 0.76 | 0.35–1.67 | 0.487 |
| Drug use in life (yes) | 0.66 | 0.40–1.06 | 0.087 | 0.52 | 0.27–1.01 | 0.053 |
| Recent tobacco use (sim) | 0.49 | 0.31–0.78 | 0.003 | 0.43 | 0.23–0.80 | 0.009 |
| Alcohol use during follow-up (yes) | 1.00 | 0.58–1.71 | 0.991 | 0.75 | 0.41–1.36 | 0.335 |
| Drug use during follow-up (yes) | 0.66 | 0.34–1.28 | 0.222 | 0.39 | 0.21–0.73 | 0.004 |
CD4+: CD4+T lymphocites; MSM: men who have sex with men; IDU: injecting drug user; MTR: multiple-tablet regimen; PI: protease inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitor; AR: adverse reaction; ARV: antiretroviral drug; ART: antiretroviral therapy
a Clinical classification according to adapted criteria of Centers for Disease Control and Prevention.
b Replacement of an initially prescribed active ingredient by another.